BR112021015466A2 - Materiais e métodos para tratar uma doença neurodegenerativa - Google Patents

Materiais e métodos para tratar uma doença neurodegenerativa Download PDF

Info

Publication number
BR112021015466A2
BR112021015466A2 BR112021015466-3A BR112021015466A BR112021015466A2 BR 112021015466 A2 BR112021015466 A2 BR 112021015466A2 BR 112021015466 A BR112021015466 A BR 112021015466A BR 112021015466 A2 BR112021015466 A2 BR 112021015466A2
Authority
BR
Brazil
Prior art keywords
fenofibrate
kaempferol
fact
subject
disease
Prior art date
Application number
BR112021015466-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Howard J. Federoff
Sudhakar Raja Subramaniam
Massimo S. FIANDACA
Mark E. Mapstore
Xiaomin Su
Original Assignee
The Regents Of The University Of California
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California, Georgetown University filed Critical The Regents Of The University Of California
Publication of BR112021015466A2 publication Critical patent/BR112021015466A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021015466-3A 2019-02-05 2020-02-05 Materiais e métodos para tratar uma doença neurodegenerativa BR112021015466A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962801271P 2019-02-05 2019-02-05
US62/801,271 2019-02-05
PCT/US2020/016820 WO2020163493A2 (en) 2019-02-05 2020-02-05 Materials and methods for treating a neurodegenerative disease

Publications (1)

Publication Number Publication Date
BR112021015466A2 true BR112021015466A2 (pt) 2021-10-19

Family

ID=71947875

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021015466-3A BR112021015466A2 (pt) 2019-02-05 2020-02-05 Materiais e métodos para tratar uma doença neurodegenerativa

Country Status (9)

Country Link
US (1) US20220401404A1 (https=)
EP (1) EP3930711A4 (https=)
JP (1) JP2022523919A (https=)
CN (1) CN114007607A (https=)
AU (1) AU2020219140A1 (https=)
BR (1) BR112021015466A2 (https=)
CA (1) CA3129050A1 (https=)
MX (1) MX2021009413A (https=)
WO (1) WO2020163493A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021022270A2 (pt) * 2019-05-06 2022-01-11 Univ California Materiais e métodos para tratar degeneração macular relacionada à idade
CN115429788B (zh) * 2022-10-24 2023-11-21 上海中医药大学附属岳阳中西医结合医院 一种治疗脱髓鞘疾病的药物及应用
CN119454686A (zh) * 2024-08-06 2025-02-18 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） 山柰酚或含有山柰酚的组合物在制备治疗和/或缓解多发性硬化症药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1850840A2 (en) 2005-01-13 2007-11-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
WO2009147009A2 (en) * 2008-06-06 2009-12-10 Nicox S.A. Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
US20130252924A1 (en) * 2010-11-11 2013-09-26 Akron Molecules Gmbh Compounds and Methods for Treating Pain
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof
CN105636582A (zh) * 2013-09-18 2016-06-01 乔治城大学 用非诺贝特及其类似物治疗神经退行性疾病
CN109069450A (zh) * 2016-02-05 2018-12-21 法奈克斯公司 神经障碍的新的组合疗法

Also Published As

Publication number Publication date
WO2020163493A2 (en) 2020-08-13
WO2020163493A9 (en) 2020-11-19
US20220401404A1 (en) 2022-12-22
EP3930711A4 (en) 2023-01-11
JP2022523919A (ja) 2022-04-27
CN114007607A (zh) 2022-02-01
EP3930711A2 (en) 2022-01-05
MX2021009413A (es) 2022-01-18
CA3129050A1 (en) 2020-08-13
WO2020163493A3 (en) 2020-10-22
AU2020219140A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
Henrich et al. Mitochondrial dysfunction in Parkinson’s disease–a key disease hallmark with therapeutic potential
Qiao et al. Sodium butyrate exacerbates Parkinson’s disease by aggravating neuroinflammation and colonic inflammation in MPTP-induced mice model
Xu et al. Melatonin alleviates cognition impairment by antagonizing brain insulin resistance in aged rats fed a high‐fat diet
Ledeen et al. Gangliosides, α-Synuclein, and Parkinson's disease
Lin et al. Omega-3 fatty acids regulate NLRP3 inflammasome activation and prevent behavior deficits after traumatic brain injury
JP2023153783A (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
Zhu et al. Neuroprotective effects of Astilbin on MPTP-induced Parkinson's disease mice: Glial reaction, α-synuclein expression and oxidative stress
Chung et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation
Wang et al. Cannabidiol alleviates the damage to dopaminergic neurons in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson’s disease mice via regulating neuronal apoptosis and neuroinflammation
Patel et al. Cinnamon and its metabolite protect the nigrostriatum in a mouse model of Parkinson’s disease via astrocytic GDNF
JP6483711B2 (ja) フェノフィブラート及びその類似体を用いた神経変性疾患の治療
Tutakhail et al. Neuropathology of kynurenine pathway of tryptophan metabolism
Ebner et al. Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th Cachexia Conference
BR112021015466A2 (pt) Materiais e métodos para tratar uma doença neurodegenerativa
JP2021120388A (ja) 神経保護および神経変性の治療のための組成物および方法
Tian et al. 3-N-Butyphthalide improves learning and memory in rats with vascular cognitive impairment by activating the SIRT1/BDNF pathway
Kalkman et al. Ceramides May play a central role in the pathogenesis of alzheimer’s disease: a review of evidence and horizons for discovery
KR20210102208A (ko) 신경계 질환의 치료
JP7850416B2 (ja) 細胞外小胞に含まれるｅｎａｍｐｔの産生および使用
Dai et al. Sirtuin 3 (SIRT3) improves sevoflurane-induced postoperative cognitive impairment by regulating mitochondrial oxidative stress
Wang et al. The activation of spliced X-box binding protein 1 by isorhynchophylline therapy improves diabetic encephalopathy
Moon et al. Differential effects of pioglitazone in the hippocampal CA1 region following transient forebrain ischemia in low-and high-fat diet-fed gerbils
EP3949974A1 (en) Composition for preventing or treating neuroinflammatory disorders, comprising bee venom extract as active ingredient
ES2377381B1 (es) Uso de una combinación de n-acetil-cisteína y ácido lipoico para la preparación de un medicamento útil para el tratamiento de una enfermedad con daño axonal y lesiones oxidativas concomitantes.
Zhang et al. Adiponectin targets the AMPK/mTOR signaling pathway to alleviate cognitive impairment in epilepsy

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2865 DE 02-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.